Clinical and Laboratory Experiences During the COVID Pandemic: Biomarker Associations with Neurologic and Systemic Symptoms

Creative Commons License

Bülbül N. G., Erdoğan E., Atmaca M. M., Florentina Ateş M., Selbest B., Eren F., ...Daha Fazla

1st APPLIED NEUROPSYCHIATRY SUMMIT, Batumi, Gürcistan, 23 - 25 Mart 2025, ss.10-12, (Özet Bildiri)

  • Yayın Türü: Bildiri / Özet Bildiri
  • Basıldığı Şehir: Batumi
  • Basıldığı Ülke: Gürcistan
  • Sayfa Sayıları: ss.10-12
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Erciyes Üniversitesi Adresli: Evet

Özet

Background: COVID-19 is a multisystem disease that manifests not only respiratory but also neurological

and systemic symptoms. In this study, we evaluated the clinical and laboratory experiences obtained

during the pandemic and the relationship between biomarkers and clinical symptoms.

Method: 423 COVID-19 patients were included in the study. Demographic data, disease history,

comorbidities and symptoms were recorded. Neurologic symptoms included headache, dizziness,

distraction, difficulty understanding, difficulty walking and epileptic seizures. Systemic symptoms included

fatigue, muscle aches and joint pains. Laboratory parameters included CRP, D-dimer, LDH, NSE, GFAP,

S100B, lymphocyte and neutrophil levels.Results: Significant correlations were found between neurologic symptoms such as headache, distraction

and comprehension difficulties and CRP (p<0.001), D-dimer (p<0.001) and LDH (p=0.042) levels. NSE

and GFAP levels were significantly lower in patients with comprehension difficulties (p=0.023, p=0.035).

Lymphocyte levels were higher in those with distractibility (p=0.009). D-dimer and LDH levels were

significantly higher in patients with acute cerebrovascular events.

Conclusion: The neurologic effects of COVID-19 are associated with inflammation, vascular dysfunction

and neuronal/glial damage. The findings provide important insights into understanding the disease course

by linking biomarkers with clinical symptoms.